Relay Therapeutics Inc
Fechado
SetorSaúde
18.84 -0.21
Visão Geral
Variação de preço das ações
24h
Mín
18.66
Máximo
19.02
Rendimento | -10M -84M |
|---|---|
Vendas | -2.7M 350K |
EPS | -0.41 |
Margem de lucro | -23,916.286 |
Funcionários | 202 |
EBITDA | -10M -83M |
Próximos Ganhos | 5 de nov. de 2026 |
|---|
Capitalização de Mercado | 80M 4.2B |
|---|---|
Abertura anterior | 19.05 |
Fecho anterior | 18.84 |
Sentimento de Notícias
By Acuity
50%
50%
126 / 339 Ranking em Healthcare
Relay Therapeutics Inc Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
Comparação entre Pares
Variação de preço
Relay Therapeutics Inc Previsão
Sentimento
By Acuity
126 / 339 Ranking em Saúde
Sentimento de Notícias
Neutral
Volatilidade
Abaixo da média
Volume de Notícias (RCV)
Abaixo da média
Informação Financeira
Custos administrativos e de venda
Custos Operacionais
Lucro antes de imposto
Vendas
Custo das vendas
Lucro bruto sobre vendas
Despesa com juros da dívida
EBITDA
Resultado Operacional
$
Sobre Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.